Video

Dr. Dent on Final LOTUS Findings in TNBC

Rebecca Dent, MD, discusses the findings from the phase 2 LOTUS trial that treated patients with inoperable locally advanced/metastatic triple-negative breast cancer with first-line ipatasertib plus paclitaxel.

Rebecca Dent, MD, senior consultant and head of Medical Oncology Department, National Cancer Center, Singapore, discusses the findings from the phase 2 LOTUS trial that treated patients with inoperable locally advanced/metastatic triple-negative breast cancer (TNBC) with first-line ipatasertib plus paclitaxel.

At the 2020 ESMO Breast Cancer Virtual Meeting, the data for the final overall survival (OS) outcomes in the phase 2 LOTUS trial were presented, says Dent; there are about 60 patients in each arm. The overall primary endpoint was PFS and researchers saw a prolonged benefit in the biomarker-positive population, as well as the intent-to-treat population. In the intent-to-treat population, ipatasertib/paclitaxel improved the median OS by 9 months, leading to a median OS of 25.8 months.

A phase 3 trial will be needed to confirm results; however, investigators saw a hazard ratio (HR) of .8 and an improvement of about 15% in 1-year OS.

When looking at the overall biomarker subset, which included PIK3CA/AKT1/PTEN mutations, as defined by next-generation sequencing, all of these showed numerical improvements in OS with the combination, but the numbers are too small at this point, Dent adds. Moreover, patients who were 50 years and older had an improvement in OS from 15 to 35 months, leading to a 60% reduction in the risk of death. This patient subgroup might be more susceptible to AKT inhibition but this is hypothesis generating, concludes Dent.

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
Adam M. Brufsky, MD, PhD, FACP
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Shipra Gandhi, MD